Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
08:00am, Friday, 25'th Jul 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Managem
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
08:30am, Friday, 27'th Jun 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab
Omeros Announces Webcast Details for Annual Meeting of Shareholders
08:30am, Tuesday, 24'th Jun 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, Jun
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision
12:53pm, Tuesday, 10'th Jun 2025
H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation OMER with a Buy rating and a price forecast of $9.
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)
10:36am, Tuesday, 03'rd Jun 2025
Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster
11:12pm, Tuesday, 27'th May 2025
Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros fac
Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript
09:07pm, Thursday, 15'th May 2025
Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript
Omeros Corporation Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 15'th May 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: N
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
05:05pm, Monday, 12'th May 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after th
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
10:35am, Monday, 12'th May 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limi
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
08:41am, Monday, 12'th May 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limi
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Applicati
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
03:06pm, Friday, 11'th Apr 2025
Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML).
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
09:10am, Thursday, 10'th Apr 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur
